Farallon Capital Management LLC Tricida, Inc. Transaction History

Farallon Capital Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$21.21 - $31.55 $10.6 Million - $15.8 Million	-500,000 Reduced 50.0%	500,000 $13.7 Million
Q4 2019 Feb 13, 2020	BUY	$29.6 - $43.71 $14.8 Million - $21.9 Million	500,000 Added 100.0%	1,000,000 $37.7 Million
Q3 2019 Nov 14, 2019	BUY	$29.87 - $42.22 $14.9 Million - $21.1 Million	500,000 New	500,000 $15.4 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.